Cufence

trientine dihydrochloride · Univar Solutions BV
AUTHORISED IN THE EU

What Cufence is used for

Cufence is indicated for the treatment of Wilson’s disease in patients intolerant to D-Penicillamine therapy, in adults and children aged 5 years or older.

Approved use, as published by the European Medicines Agency.

Key facts

Brand
Cufence
Active substance
trientine dihydrochloride
Disease area
Hepatolenticular Degeneration
Medicine group
Other alimentary tract and metabolism products
ATC code
A16A
Marketing authorisation holder
Univar Solutions BV
Authorised in the EU since
2019

Official information

In India

Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.

Common questions

What is Cufence used for?

Cufence is indicated for the treatment of Wilson’s disease in patients intolerant to D-Penicillamine therapy, in adults and children aged 5 years or older.

What is the active substance in Cufence?

Cufence contains trientine dihydrochloride.

Who makes Cufence?

The EU marketing authorisation holder is Univar Solutions BV.

Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.

← All specialty medicines, EU

For information only, not medical advice. This page is a plain-language summary written from standard prescribing information and the public guides linked below. Brands sometimes change their formula, so always check the composition printed on the pack. Doses here are typical adult doses; yours may differ. Do not start, stop or change a medicine without your doctor or pharmacist, and keep all medicines away from children. In an emergency, call 112 (India) or your local emergency number.